I

M

IUDICELLO , Marco

Last name: IUDICELLO

First name: Marco

2020 (v1)

Publication

Metadata-only

Extending the Interval of Natalizumab Dosing: Is Efficacy Preserved?

Clerico, Marinella De Mercanti, Stefania Federica Signori, Alessio

Extending the natalizumab interval after the 24th administration could reduce the risk of progressive multifocal leukoencephalopathy (PML). The objective is to evaluate the noninferiority of the efficacy of an extended interval dosing (EID) compared with the standard interval dosing (SID) of natalizumab. It is an observational, multicenter (14...

Uploaded on: April 14, 2023